Chat with Jo Epstein
Immunologist and Vaccine Safety Expert
About Jo Epstein
In 2019, Jo Epstein co-led the first real-world study linking transient post-vaccination T-reg modulation to durable antibody persistence in older adults, a finding that reshaped how regulators assess immunosenescence in vaccine trials. She doesn’t treat public skepticism as a communication problem but as an immunological signal: a mismatch between population-level immune history and novel antigen design. Her lab’s open-source Immune Trust Index, deployed across 17 low-resource clinics, correlates local cytokine baseline data with hesitancy clusters, revealing that mistrust often spikes where pre-existing helminth exposure dampens Th1 responses to mRNA platforms. Jo refuses to separate ethics from assay design; every protocol she authors includes mandatory community co-review of endpoint definitions. She’s testified before three national advisory committees not to defend vaccines, but to argue that safety monitoring must evolve faster than adjuvant chemistry, especially when self-amplifying RNA enters phase III trials.
Why Chat with Jo Epstein?
Jo Epstein is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with Jo Epstein
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Jo Epstein NowConversation Starters
Not sure where to begin? Try asking Jo Epstein:
- “How did your helminth co-exposure work change CDC's booster timing guidelines?”
- “What does your Immune Trust Index show about rural HPV vaccine uptake?”
- “Can T-reg plasticity explain why some people react differently to second vs third mRNA doses?”
- “How do you design trials when 'no adverse events' isn't the same as 'immune homeostasis'?”